当前位置: X-MOL 学术Cancer Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Acalabrutinib Approved for MCL
Cancer Discovery ( IF 29.7 ) Pub Date : 2018-01-01 , DOI: 10.1158/2159-8290.cd-nb2017-158
American Association for Cancer Research

The FDA granted accelerated approval to the second-generation BTK inhibitor acalabrutinib, which, because of its increased selectivity, seems to cause fewer side effects than ibrutinib, previously the only BTK inhibitor on the market.



中文翻译:

Acalabrutinib获准用于MCL

FDA批准了第二代BTK抑制剂acalabrutinib的加速批准,由于其选择性的提高,它引起的副作用似乎比以前市场上唯一的BTK抑制剂ibrutinib少。

更新日期:2018-01-08
down
wechat
bug